Thyroid Dysfunction Induced by Anti-PD-1 Therapy in Patients With Advanced Carcinoma

Qilu Hospital of Shandong University100 enrolled

Overview

In this study, we monitored patients with advanced malignant tumors who received anti-PD-1 therapy to observe the characteristic of anti-PD-1 therapy-induced thyroid dysfunction and its correlation with prognosis.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Carcinoma

Interventions

no interventionOTHER

This is an observational study so not involved intervention

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Eighteen years or older * Confirmed diagnosis of malignancy * Received anti-PD-1 therapy Exclusion Criteria: * Thyroid malignancy or history of thyroid malignancy * Thyroid dysfunction before anti-PD-1 therapies * Previous ICIs treatment * Less than 2 cycles of anti-PD-1 treatment * No thyroid function monitoring during treatment * Known pituitary disease * Pregnancy.

Locations (1)

Qilu Hospital, Shandong University

Jinan, Shandong, China

Outcomes

Primary Outcomes

Progression-free survival

The time between initiation of anti-PD-1 therapy and disease progression or death, whichever came first.

Time frame: Through study completion, an average of 17 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.